Bots, editor, reviewer, Administrators
13,941
edits
WikiJournalClub:High-priority articles: Difference between revisions
Jump to navigation
Jump to search
WikiJournalClub:High-priority articles (view source)
Revision as of 21:15, 14 December 2023
, 14 December 2023BELINDA now usable
No edit summary |
(BELINDA now usable) |
||
| Line 16: | Line 16: | ||
* 2022 {{create article link|DESTINY-Breast04}}: Trastuzumab deruxtecan in previously treated HER2-Low breast cancer [https://www.nejm.org/doi/full/10.1056/NEJMoa2203690] | * 2022 {{create article link|DESTINY-Breast04}}: Trastuzumab deruxtecan in previously treated HER2-Low breast cancer [https://www.nejm.org/doi/full/10.1056/NEJMoa2203690] | ||
* 2021 {{create article link|TOMAHAWK}}: Angiography for out of hospital cardiac arrest [https://www.nejm.org/doi/full/10.1056/NEJMoa2101909] | * 2021 {{create article link|TOMAHAWK}}: Angiography for out of hospital cardiac arrest [https://www.nejm.org/doi/full/10.1056/NEJMoa2101909] | ||
* 2021 {{create article link|AXIOMATIC-TKR}}: Milvexian for VTE prophylaxis after TKR [https://www.nejm.org/doi/full/10.1056/NEJMoa2113194] | * 2021 {{create article link|AXIOMATIC-TKR}}: Milvexian for VTE prophylaxis after TKR [https://www.nejm.org/doi/full/10.1056/NEJMoa2113194] | ||
* 2021 {{create article link|ADAPTABLE}}: ASA 81 vs. 325 for CVD secondary prevention [https://www.nejm.org/doi/full/10.1056/NEJMoa2102137] | * 2021 {{create article link|ADAPTABLE}}: ASA 81 vs. 325 for CVD secondary prevention [https://www.nejm.org/doi/full/10.1056/NEJMoa2102137] | ||